Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – VIDEO

Bioxcel Therapeutics Inc.'s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxcel CEO, talks about the potential with Lee Landenberger in the latest BioWorld Insider podcast.


Отзывы


Podcastly – the best platform for podcasters and podcast lovers. More than 10 millions of audio content that available on Android/iOS/Web/Desktop and Telegram.